Kishore M Gadde

Title(s)Professor In Residence, Surgery
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Pharmacotherapy in conjunction with lifestyle counseling for management of weight regain after bariatric surgery (PROJECT-BARI)
    NIH R01DK129936Sep 8, 2021 - Jul 31, 2026
    Role: Principal Investigator
    Zonisamide for Weight Reduction in Obese Adults
    NIH R01DK067352Apr 1, 2005 - Mar 31, 2010
    Role: Principal Investigator
    1/22 Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) - Clinical Center
    NIH U01DK048377Aug 15, 1994 - Jan 31, 2022
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Risk of Type 2 Diabetes Among Individuals with Excess Weight: Weight Trajectory Effects. Curr Diab Rep. 2022 Sep; 22(9):471-479. Owora AH, Allison DB, Zhang X, Gletsu-Miller N, Gadde KM. PMID: 35781782.
      View in: PubMed   Mentions:    Fields:    
    2. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. Circulation. 2022 05 31; 145(22):1632-1641. Goldberg RB, Orchard TJ, Crandall JP, Boyko EJ, Budoff M, Dabelea D, Gadde KM, Knowler WC, Lee CG, Nathan DM, Watson K, Temprosa M, Diabetes Prevention Program Research Group*. PMID: 35603600; PMCID: PMC9179081.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    3. The Role of Calorie Restriction in the Prevention of Cardiovascular Disease. Curr Atheroscler Rep. 2022 04; 24(4):235-242. Perry CA, Gadde KM. PMID: 35107761.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    4. Obesity, Body Composition, and Sex Hormones: Implications for Cardiovascular Risk. Compr Physiol. 2021 12 29; 12(1):2949-2993. Singh P, Covassin N, Marlatt K, Gadde KM, Heymsfield SB. PMID: 34964120.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Long-acting amylin analogue for weight reduction. Lancet. 2021 12 11; 398(10317):2132-2134. Gadde KM, Allison DB. PMID: 34798059.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care. 2021 12; 44(12):2775-2782. Lee CG, Heckman-Stoddard B, Dabelea D, Gadde KM, Ehrmann D, Ford L, Prorok P, Boyko EJ, Pi-Sunyer X, Wallia A, Knowler WC, Crandall JP, Temprosa M, Diabetes Prevention Program Research Group, Diabetes Prevention Program Research Group:. PMID: 34697033; PMCID: PMC8669534.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Targeting visceral adiposity with pharmacotherapy. Lancet Diabetes Endocrinol. 2021 09; 9(9):551-552. Gadde KM, Heymsfield SB. PMID: 34358470.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Diabetes Care. 2021 06; 44(6):1433-1442. Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P. PMID: 34016612; PMCID: PMC8247525.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    9. Testosterone supplementation upregulates androgen receptor expression and translational capacity during severe energy deficit. Am J Physiol Endocrinol Metab. 2020 10 01; 319(4):E678-E688. Howard EE, Margolis LM, Berryman CE, Lieberman HR, Karl JP, Young AJ, Montano MA, Evans WJ, Rodriguez NR, Johannsen NM, Gadde KM, Harris MN, Rood JC, Pasiakos SM. PMID: 32776828; PMCID: PMC7750513.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    10. The limits and challenges of antiobesity pharmacotherapy. Expert Opin Pharmacother. 2020 Aug; 21(11):1319-1328. Gadde KM, Atkins KD. PMID: 32292094; PMCID: PMC7523877.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    11. Effects of Testosterone Supplementation on Ghrelin and Appetite During and After Severe Energy Deficit in Healthy Men. J Endocr Soc. 2020 Apr 01; 4(4):bvaa024. Karl JP, Berryman CE, Harris MN, Lieberman HR, Gadde KM, Rood JC, Pasiakos SM. PMID: 32258956; PMCID: PMC7101089.
      View in: PubMed   Mentions: 1  
    12. Effects of testosterone supplementation on body composition and lower-body muscle function during severe exercise- and diet-induced energy deficit: A proof-of-concept, single centre, randomised, double-blind, controlled trial. EBioMedicine. 2019 Aug; 46:411-422. Pasiakos SM, Berryman CE, Karl JP, Lieberman HR, Orr JS, Margolis LM, Caldwell JA, Young AJ, Montano MA, Evans WJ, Vartanian O, Carmichael OT, Gadde KM, Johannsen NM, Beyl RA, Harris MN, Rood JC. PMID: 31358477; PMCID: PMC6711889.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    13. Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019 05 21; 170(10):682-690. Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM, Diabetes Prevention Program Research Group. PMID: 31009939; PMCID: PMC6829283.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    14. Weight Loss Medications in the Treatment of Obesity and Hypertension. Curr Hypertens Rep. 2019 02 12; 21(2):16. Cohen JB, Gadde KM. PMID: 30747357; PMCID: PMC6415530.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    15. Relationship Between Perceptions of Obesity Causes and Weight Loss Expectations Among Adults. J Nutr Educ Behav. 2019 01; 51(1):86-90. Daigle KM, Gang CH, Kopping MF, Gadde KM. PMID: 30318272; PMCID: PMC6352733.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Glial acetate metabolism is increased following a 72-h fast in metabolically healthy men and correlates with susceptibility to hypoglycemia. Acta Diabetol. 2018 Oct; 55(10):1029-1036. McDougal DH, Darpolor MM, DuVall MA, Sutton EF, Morrison CD, Gadde KM, Redman LM, Carmichael OT. PMID: 29931424; PMCID: PMC6153507.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    17. Obesity: Pathophysiology and Management. J Am Coll Cardiol. 2018 01 02; 71(1):69-84. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. PMID: 29301630; PMCID: PMC7958889.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    18. Pharmacotherapy for Patients with Obesity. Clin Chem. 2018 01; 64(1):118-129. Gadde KM, Apolzan JW, Berthoud HR. PMID: 29054924; PMCID: PMC7379842.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    19. Physiological and psychological effects of testosterone during severe energy deficit and recovery: A study protocol for a randomized, placebo-controlled trial for Optimizing Performance for Soldiers (OPS). Contemp Clin Trials. 2017 07; 58:47-57. Pasiakos SM, Berryman CE, Karl JP, Lieberman HR, Orr JS, Margolis LM, Caldwell JA, Young AJ, Montano MA, Evans WJ, Vartanian O, Carmichael OT, Gadde KM, Harris M, Rood JC. PMID: 28479217.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    20. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. Curr Diab Rep. 2017 05; 17(5):34. Gadde KM, Pritham Raj Y. PMID: 28378293.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    21. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017 07; 19(7):979-988. Gadde KM, Vetter ML, Iqbal N, Hardy E, Öhman P, DURATION-NEO-2 study investigators. PMID: 28205322; PMCID: PMC5485171.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    22. Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement? Qual Life Res. 2016 May; 25(5):1237-44. Kolotkin RL, Gadde KM, Peterson CA, Crosby RD. PMID: 26446094.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    23. Weight loss: slow and steady does not win the race. Lancet Diabetes Endocrinol. 2014 Dec; 2(12):927-8. Martin CK, Gadde KM. PMID: 25459210.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Obesity medications reduce total body weight by 3-9% compared with placebo, when combined with lifestyle changes. Evid Based Nurs. 2015 Jan; 18(1):29-30. Gadde KM, Yancy WS. PMID: 24842056.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment. Diabetes Obes Metab. 2014 Aug; 16(8):766-8. Shin JH, Gadde KM, Østbye T, Bray GA. PMID: 25123600; PMCID: PMC4135527.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    26. Combination phentermine/topiramate for obesity treatment in primary care: a review. Postgrad Med. 2014 Mar; 126(2):110-6. Xiong GL, Gadde KM. PMID: 24685974.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. Expert Opin Pharmacother. 2014 Apr; 15(6):809-22. Gadde KM. PMID: 24548209.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    28. Weight loss treatment in obese adults. JAMA. 2013 Dec 18; 310(23):2568. Gadde KM. PMID: 24347000; PMCID: PMC9365294.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013 Nov; 21(11):2163-71. Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. PMID: 24136928.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    30. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013; 6:131-9. Shin JH, Gadde KM. PMID: 23630428; PMCID: PMC3626409.
      View in: PubMed   Mentions: 15  
    31. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med. 2012 Nov 12; 172(20):1557-64. Gadde KM, Kopping MF, Wagner HR, Yonish GM, Allison DB, Bray GA. PMID: 23147455; PMCID: PMC3753218.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    32. Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2012 Jun; 32(3):341-5. Vander Wal JS, Gang CH, Griffing GT, Gadde KM. PMID: 22544016.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    33. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012 Feb; 95(2):297-308. Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. PMID: 22158731; PMCID: PMC3260065.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansCTClinical Trials
    34. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Drugs Today (Barc). 2011 Dec; 47(12):903-14. Bays HE, Gadde KM. PMID: 22348915.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    35. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb; 20(2):330-42. Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. PMID: 22051941; PMCID: PMC3270297.
      View in: PubMed   Mentions: 142     Fields:    Translation:Humans
    36. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Apr 16; 377(9774):1341-52. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. PMID: 21481449.
      View in: PubMed   Mentions: 204     Fields:    Translation:HumansCTClinical Trials
    37. Sexual functioning in obese adults enrolling in a weight loss study. J Sex Marital Ther. 2011; 37(3):224-35. Ostbye T, Kolotkin RL, He H, Overcash F, Brouwer R, Binks M, Syrjala KL, Gadde KM. PMID: 21512941; PMCID: PMC3201733.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    38. Combination therapy for obesity and metabolic disease. Curr Opin Endocrinol Diabetes Obes. 2009 Oct; 16(5):353-8. Gadde KM, Allison DB. PMID: 19625958.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    39. Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS One. 2009 Aug 13; 4(8):e6624. Elobeid MA, Padilla MA, McVie T, Thomas O, Brock DW, Musser B, Lu K, Coffey CS, Desmond RA, St-Onge MP, Gadde KM, Heymsfield SB, Allison DB. PMID: 19675667; PMCID: PMC2720539.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    40. Sample size in obesity trials: patient perspective versus current practice. Med Decis Making. 2010 Jan-Feb; 30(1):68-75. Allison DB, Elobeid MA, Cope MB, Brock DW, Faith MS, Vander Veur S, Berkowitz R, Cutter G, McVie T, Gadde KM, Foster GD. PMID: 19675318; PMCID: PMC2914621.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    41. The effect of acute tryptophan depletion on emotional distraction and subsequent memory. Soc Cogn Affect Neurosci. 2009 Dec; 4(4):357-68. Wang L, Mullette-Gillman OA, Gadde KM, Kuhn CM, McCarthy G, Huettel SA. PMID: 19628700; PMCID: PMC2799951.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    42. Combination pharmaceutical therapies for obesity. Expert Opin Pharmacother. 2009 Apr; 10(6):921-5. Gadde KM, Allison DB. PMID: 19351275; PMCID: PMC4780673.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    43. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009 Jan; 17(1):30-9. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA. PMID: 18997675.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansAnimals
    44. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology. 2008 Nov; 33(12):2922-33. Wallingford NM, Sinnayah P, Bymaster FP, Gadde KM, Krishnan RK, McKinney AA, Landbloom RP, Tollefson GD, Cowley MA. PMID: 18322467.
      View in: PubMed   Mentions: 9     Fields:    Translation:AnimalsCells
    45. Childhood socioeconomic status and serotonin transporter gene polymorphism enhance cardiovascular reactivity to mental stress. Psychosom Med. 2008 01; 70(1):32-9. Williams RB, Marchuk DA, Siegler IC, Barefoot JC, Helms MJ, Brummett BH, Surwit RS, Lane JD, Kuhn CM, Gadde KM, Ashley-Koch A, Svenson IK, Suarez EC, Schanberg SM. PMID: 18158371.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    46. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry. 2007 Aug; 68(8):1226-9. Gadde KM, Yonish GM, Foust MS, Wagner HR. PMID: 17854247.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    47. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care. 2007 Jun; 30(6):1480-6. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A, OBD-202 Study Group. PMID: 17363756.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    48. Escitalopram treatment of trichotillomania. Int Clin Psychopharmacol. 2007 Jan; 22(1):39-42. Gadde KM, Ryan Wagner H, Connor KM, Foust MS. PMID: 17159458.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    49. Bupropion for weight reduction. Expert Rev Neurother. 2007 Jan; 7(1):17-24. Gadde KM, Xiong GL. PMID: 17187492.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    50. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation. 2006 Aug 29; 114(9):974-84. Gadde KM, Allison DB. PMID: 16940206.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    51. Effect of rimonabant on weight and cardiometabolic risk factors. JAMA. 2006 Aug 09; 296(6):649-50; author reply 650-1. Gadde KM. PMID: 16896103.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    52. Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol. 2006 Aug; 26(4):373-8. Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JR. PMID: 16855454.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    53. Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. J Clin Psychopharmacol. 2006 Aug; 26(4):409-13. Gadde KM, Zhang W, Foust MS. PMID: 16855461.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    54. Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond). 2006 Jul; 30(7):1138-42. Gadde KM, Yonish GM, Wagner HR, Foust MS, Allison DB. PMID: 16418753.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    55. Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction. Curr Drug Targets Cardiovasc Haematol Disord. 2005 Dec; 5(6):549-56. Gadde KM. PMID: 16503875.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. J Clin Psychopharmacol. 2005 Jun; 25(3):243-9. Vitiello B, Shader RI, Parker CB, Ritz L, Harlan W, Greenblatt DJ, Gadde KM, Krishnan KR, Davidson JR. PMID: 15876903.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCTClinical Trials
    57. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005 Jan; 66(1):49-51. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. PMID: 15669888.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    58. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004 Oct; 61(10):1005-13. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM. PMID: 15466674.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCTClinical Trials
    59. Assessing patient beliefs in a clinical trial of Hypericum perforatum in major depression. Depress Anxiety. 2004; 20(3):114-22. Bann CM, Parker CB, Bradwejn J, Davidson JR, Vitiello B, Gadde KM. PMID: 15549690.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimals
    60. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003 Apr 09; 289(14):1820-5. Gadde KM, Franciscy DM, Wagner HR, Krishnan KR. PMID: 12684361.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    61. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002 Oct; 10(10):1049-56. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A. PMID: 12376586.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    62. Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology. 2003 Mar; 28(3):533-41. Williams RB, Marchuk DA, Gadde KM, Barefoot JC, Grichnik K, Helms MJ, Kuhn CM, Lewis JG, Schanberg SM, Stafford-Smith M, Suarez EC, Clary GL, Svenson IK, Siegler IC. PMID: 12629534.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    63. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002 Jul; 10(7):633-41. Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM. PMID: 12105285.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    64. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002 04 10; 287(14):1807-14. Hypericum Depression Trial Study Group, Davidson JR, Gadde KM, Fairbank JA, Krishnan KRR, Califf RM, Binanay C, Parker CB, Pugh N, Hartwell TD, Vitiello B, Ritz L, Severe J, Cole JO, de Battista C, Doraiswamy PM, Feighner JP, Keck P, Kelsey J, Lin KM, Londborg PD, Nemeroff CB, Schatzberg AF, Sheehan DV, Srivastava RK, Taylor L, Trivedi MH, Weisler RH. PMID: 11939866.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCTClinical Trials
    65. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001 Sep; 9(9):544-51. Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, Krishnan KR. PMID: 11557835.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    66. Central nervous system serotonin function and cardiovascular responses to stress. Psychosom Med. 2001 Mar-Apr; 63(2):300-5. Williams RB, Marchuk DA, Gadde KM, Barefoot JC, Grichnik K, Helms MJ, Kuhn CM, Lewis JG, Schanberg SM, Stafford-Smith M, Suarez EC, Clary GL, Svenson IK, Siegler IC. PMID: 11292279.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    67. Psychoneuroendocrinology and brain imaging in depression. Psychiatr Clin North Am. 1998 Jun; 21(2):465-72. Krishnan KR, Gadde KM, Kim YD. PMID: 9670237.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    68. Diltiazem effect on carbamazepine levels in manic depression. J Clin Psychopharmacol. 1990 Oct; 10(5):378-9. Gadde K, Calabrese JR. PMID: 2258457.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Kishore's Networks
    Concepts (285)
    Derived automatically from this person's publications.
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _